An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

Trial Profile

An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs VC 02 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors ViaCyte Inc
  • Most Recent Events

    • 05 Jan 2018 According to a ViaCyte Inc. media release, the first patients have been implanted in Cohort 2 with a potentially efficacious dose of the company's PEC-Direct islet cell replacement therapy in this trial.
    • 07 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 19 May 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top